Piramal Pharma cuts emissions, achieves zero USFDA OAI observations

Piramal Pharma strengthens operations with a 22.6% emissions reduction and 41% renewable energy adoption. The company reported zero USFDA OAI observations, signaling strong compliance. These improvements reflect enhanced operational efficiency and ESG commitment. Positive for long-term sustainability and regulatory standing.

📊 STOCKS: PEL | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #ESG